Abstract
We review the practical importance of lobar atrophy in frontotemporal dementia (FTD), for diagnosis and prognosis. We discuss specific patterns of frontotemporal atrophy that denote clinical and pathological subtypes of FTD (e.g. semantic dementia). We also discuss the unsatisfactory clinical experience of interpreting MRI scans in individual FTD cases, especially the behavioural presentations (without aphasic or motor impairments). This issue is explored by examining the FTD phenocopy concept. Lobar atrophy emerges as a key observation in defining behavioural FTD patients whose symptoms are likely to progress. In a situation where objective clinical data are few, we highlight the importance of applying caution before diagnosing FTD is the absence of visible brain atrophy.
Keywords: Frontotemporal dementia, lobar atrophy, phenocopy, PiD, frontal degeneration, CBD, MND features, bvFTD, degenerative pathologies, SD-mimic, gross anatomical change, hippocampal atrophy, PNFA, predominant temporal atrophy
Current Alzheimer Research
Title: Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Volume: 8 Issue: 3
Author(s): R. R. Davies and C. M. Kipps
Affiliation:
Keywords: Frontotemporal dementia, lobar atrophy, phenocopy, PiD, frontal degeneration, CBD, MND features, bvFTD, degenerative pathologies, SD-mimic, gross anatomical change, hippocampal atrophy, PNFA, predominant temporal atrophy
Abstract: We review the practical importance of lobar atrophy in frontotemporal dementia (FTD), for diagnosis and prognosis. We discuss specific patterns of frontotemporal atrophy that denote clinical and pathological subtypes of FTD (e.g. semantic dementia). We also discuss the unsatisfactory clinical experience of interpreting MRI scans in individual FTD cases, especially the behavioural presentations (without aphasic or motor impairments). This issue is explored by examining the FTD phenocopy concept. Lobar atrophy emerges as a key observation in defining behavioural FTD patients whose symptoms are likely to progress. In a situation where objective clinical data are few, we highlight the importance of applying caution before diagnosing FTD is the absence of visible brain atrophy.
Export Options
About this article
Cite this article as:
R. Davies R. and M. Kipps C., Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563818
DOI https://dx.doi.org/10.2174/156720511795563818 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Converging Pathways in the Occurrence of Endoplasmic Reticulum (ER) Stress in Huntingtons Disease
Current Molecular Medicine Classification of Acetylcholinesterase Inhibitors and Decoys by a Support Vector Machine
Combinatorial Chemistry & High Throughput Screening The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology From the Editors Perspective: Inflammatory Glial Cells of the Nervous System: Assistants or Assassins?
Current Neurovascular Research Cholinesterase Inhibitors: From Weapons, to Pesticides, to Cognition Enhancing Drugs
Current Enzyme Inhibition A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Conference Report: 9th Clinical Trials on Alzheimer's Disease (CTAD): Marriott Marquis San Diego Marina, San Diego, CA, USA December 8-10, 2016
CNS & Neurological Disorders - Drug Targets Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Current Alzheimer Research PLA2G6 Mutations and Other Rare Causes of Neurodegeneration with Brain Iron Accumulation
Current Drug Targets Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties
Current Alzheimer Research Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review
Current Clinical Pharmacology Biomarkers of Cell Damage Induced by Oxidative Stress in Parkinsons Disease and Related Models
Central Nervous System Agents in Medicinal Chemistry Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry α-Synuclein and the Pathogenesis of Parkinsons Disease
Protein & Peptide Letters HMPAO-SPECT Can Discriminate between Patients with Subjective Cognitive Complaints with and without Cognitive Deficits and those with Mild Cognitive Impairment
Current Alzheimer Research The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews